Charities Seek Cut of Drug Royalties, Nature, July 21, 2011, Vol. 475

Early next year, a drug for cystic fibrosis is expected to come before the US Food and Drug Administration for approval. It is a moment that the Cystic Fibrosis Foundation (CFF) will have waited 12 years and invested US$75 million to witness. Approval of the drug, VX-770 — developed by Vertex Pharmaceuticals of Cambridge, Massachusetts, with support from the foundation — would provide a new treatment for patients, and a revenue stream for the charity…

Download the full article (PDF): Charities Seek Cut of Drug Royalties, Nature, July 21, 2011, Vol. 475